secwatch.observer — SEC 8-K summary
======================================

Issuer:     Certara, Inc. (CERT)
CIK:        0001827090
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001104659-26-046358
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Certara sells Regulatory & Medical Writing business to Veristat for up to $135M
-------------------------------------------------------------------------------

- Cash consideration of $100M plus up to $35M earn-out based on future performance.
- Sold business generated $50M revenue and $17M adjusted EBITDA in 2025, employing ~220 people.
- Transaction expected to close in Q2 2026 subject to customary conditions.
- Certara will update 2026 guidance after close; proceeds to be deployed for MIDD platform growth.
- Sale sharpens focus on Model-Informed Drug Development and AI-integrated modeling.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827090/000110465926046358/0001104659-26-046358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827090/000110465926046358/tm2612400d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-046358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer